ReviewJournal of cellular and molecular medicine2012
Regulatory T cell: a protection for tumour cells.
Review in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 68 citations in OpenAlex.
- The Double-Edged Sword: How Radiotherapy Shapes the Tumor Immune Microenvironment to Modulate Responses to Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
- Identification and Validation of Basement Membrane Related LncRNA Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma.Biochemical genetics · 2025Article
- Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition.Medical oncology (Northwood, London, England) · 2024Review
- Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time.Current opinion in chemical biology · 2023Review
- Review
- A new target of radiotherapy combined with immunotherapy: regulatory T cells.Frontiers in immunology · 2023Review
- Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.Advances in experimental medicine and biology · 2023Article
- Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses byFrontiers in immunology · 2023Article
- Radiation for hematologic malignancies: from cell killing to immune cell priming.Frontiers in oncology · 2023Review
- Long Noncoding RNA: Shining Stars in the Immune Microenvironment of Gastric Cancer.Frontiers in oncology · 2022Review
- Blockade of TGF-βR improves the efficacy of doxorubicin by modulating the tumor cell motility and affecting the immune cells in a melanoma model.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Inhibition of photodynamic therapy induced-immunosuppression with aminolevulinic acid leads to enhanced outcomes of tumors and pre-cancerous lesions.Oncology letters · 2021Review
- Article
- Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer.Frontiers in immunology · 2021Review
- P21 activated kinase-1 (PAK1) in macrophages is required for promotion of Th17 cell response during helminth infection.Journal of cellular and molecular medicine · 2020Article
- Virus-like particles for vaccination against cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Cancer-Derived Exosomes as Effectors of Key Inflammation-Related Players.Frontiers in immunology · 2019Review
- Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characterized by immunosuppression regulatory T cells (Tregs) play a key role in maintaining immune tolerance. A growing number of tumours have been found with Tregs accumulating in microenvironment and patients with high density of Tregs in tumour stroma get a worse prognosis, which suggests that Tregs may inhibit anti-tumour immunity in stroma, resulting in a poor prognosis. In this paper, we demonstrate the accumulation of Tregs in tumour stroma and the possible suppressive mechanisms. We also state the immunotherapy that has being used in animal and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.